Related Experiment Video
Updated: Oct 9, 2025
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.6K
Systolic dysfunction in patients with methamphetamine use and heart failure with preserved ejection fraction
Harpreet S Bhatia1, Marin Nishimura1, Armando Martinez2
1Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
International Journal of Cardiology
|December 18, 2021
Summary
Methamphetamine use (MU) in heart failure with preserved ejection fraction (HFpEF) patients may indicate hidden systolic dysfunction. Cessation of MU improves cardiac function and reduces heart failure hospitalizations.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Substance Use Disorders
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a complex condition.
- Methamphetamine use (MU) is increasingly recognized as a factor in cardiovascular disease.
- The impact of MU on cardiac function in HFpEF requires further elucidation.
Purpose of the Study:
- To investigate occult systolic dysfunction in patients with HFpEF and MU.
- To assess the effect of methamphetamine cessation on cardiac function and clinical outcomes in this population.
Main Methods:
- Retrospective cohort study of HFpEF patients with serial echocardiograms.
- Myocardial strain analysis, specifically global longitudinal strain (GLS), was used to assess systolic function.
- Patients were stratified by MU status and followed for one year, with MU cessation as a key variable.
Main Results:
- Patients with MU were younger and more frequently male than controls.
- No significant baseline difference in ejection fraction (EF) or GLS was observed.
- One-year cessation of MU was associated with significant improvement in GLS, unlike continued MU or controls.
- Abnormal baseline GLS normalized in 46% of patients who ceased MU, compared to none with continued MU.
Conclusions:
- Abnormal GLS in patients with MU and HFpEF suggests potential occult systolic dysfunction.
- Methamphetamine cessation at one year is linked to improved GLS and a reduced risk of heart failure admissions.
Keywords:
EchocardiographyHeart failure with preserved ejection fractionMethamphetamine useStrainSubstance useMore Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
96
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
96
01:17Pathophysiology of Heart Failure
2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
556
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
556
01:27Heart Failure I: Introduction
121
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
121
01:30Heart Failure V: Medical Management
45
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
45
01:20Mitral Regurgitation I: Introduction
77
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
77